Obstetric and Gynecologic Imaging

What Imaging Is Best for Ovarian Cancer Screening in High-Risk Premenopausal Women?

·
What Imaging Is Best for Ovarian Cancer Screening in High-Risk Premenopausal Women?

A 34-year-old woman with a known BRCA1 mutation sits in your exam room for her annual visit. She is asymptomatic and her physical exam is unremarkable. Her mother was diagnosed with ovarian cancer at age 45. The patient understands her elevated lifetime risk and is committed to surveillance, but she is years away from considering risk-reducing surgery. You are tasked with ordering the appropriate annual screening imaging, balancing the need for early detection against the risks of false positives and unnecessary interventions in a premenopausal patient. This article details the clinical workflow for this specific scenario, explaining why certain imaging studies are chosen and what to do with the results. Based on the American College of Radiology (ACR) Appropriateness Criteria, US color Doppler of the ovaries is rated as ‘May be appropriate’ for this indication.

Who Fits This Clinical Scenario for High-Risk Ovarian Cancer Screening?

This guidance applies specifically to asymptomatic, premenopausal adult women who are at high risk for developing ovarian cancer. Defining these terms is critical to applying the correct imaging strategy.

Inclusion Criteria:

  • Premenopausal Status: The patient is still having menstrual cycles. This is a key distinction, as the appearance of the ovaries and the differential diagnosis for adnexal findings differ significantly from postmenopausal women.
  • High-Risk Status: This is typically defined by a significantly increased lifetime risk due to genetic predisposition or strong family history. This includes, but is not limited to, women with pathogenic variants in genes such as BRCA1, BRCA2, or those associated with Lynch syndrome (MLH1, MSH2, MSH6, PMS2), as well as those with a calculated lifetime risk above 20% based on family history models.
  • Screening Context: The patient has no current symptoms concerning for ovarian cancer, such as persistent bloating, pelvic pain, or early satiety. The imaging is for surveillance purposes only.

Exclusion Criteria:
This workflow is not appropriate for patients who are symptomatic, postmenopausal, or at average risk. For instance, a premenopausal woman with acute pelvic pain would undergo a diagnostic workup, not a screening protocol. Similarly, a postmenopausal high-risk woman follows a different screening and management algorithm due to the lower likelihood of benign functional cysts. Average-risk women are not recommended for routine ovarian cancer screening with imaging.

What Diagnoses Are You Working Up in This High-Risk Scenario?

The primary goal of screening in this high-risk population is the early detection of malignancy, most commonly epithelial ovarian cancer. Because these cancers are often asymptomatic in their early stages, imaging surveillance aims to identify subtle morphologic changes before the disease becomes advanced.

However, the practical reality of imaging premenopausal ovaries is that incidental, benign findings are extremely common. Therefore, the differential diagnosis during a screening study includes a spectrum of conditions. The most common findings are benign functional cysts (e.g., follicular or corpus luteum cysts), which are a normal part of the menstrual cycle. Differentiating these from more concerning lesions is a key challenge.

Other potential findings include benign neoplasms such as mature cystic teratomas (dermoid cysts) or endometriomas, which have characteristic imaging features but can sometimes be complex in appearance. Less commonly, a screening study may identify a borderline tumor or an early-stage invasive cancer. The imaging workup is designed to characterize any detected adnexal lesion to distinguish inconsequential physiologic changes from pathology that requires further action.

Why Is Transvaginal Ultrasound the Primary Screening Study?

For high-risk premenopausal women, the combination of transvaginal ultrasound, often supplemented with color Doppler, is the established first-line imaging modality for ovarian cancer screening. The ACR rates US color Doppler ovaries, US pelvis transvaginal, and US pelvis transabdominal as ‘May be appropriate’. This rating reflects the consensus that while screening has benefits in this specific high-risk cohort, it is not recommended for the general population, and the evidence must be carefully weighed against the potential for false positives.

The rationale for using ultrasound is multifactorial:

  • Excellent Anatomic Detail: Transvaginal ultrasound provides high-resolution images of the ovarian parenchyma, allowing for detailed assessment of morphology, size, and the presence of any cystic or solid components. It is highly sensitive for detecting adnexal masses.
  • Safety and Accessibility: Ultrasound involves no ionizing radiation (0 mSv), a critical consideration for a surveillance strategy that requires repeated annual or semi-annual imaging over many years. It is also widely available and less costly than other cross-sectional imaging.
  • Functional Assessment with Doppler: The addition of color Doppler helps characterize blood flow within a lesion. While not definitive, the presence and pattern of vascularity can help distinguish between benign and potentially malignant masses, with suspicious lesions often demonstrating increased internal blood flow.

Why are other modalities rated lower for screening?

  • CT Abdomen and Pelvis: Rated ‘Usually not appropriate’. CT exposes the patient to significant ionizing radiation (☢☢☢ 1-10 mSv for a single-phase study). The cumulative dose from annual CT screening would be substantial and is not justified. Furthermore, CT has lower soft-tissue contrast resolution for evaluating internal ovarian architecture compared to ultrasound or MRI.
  • MRI Pelvis: Rated ‘Usually not appropriate’ for initial screening. While MRI offers superior soft-tissue characterization and is an excellent problem-solving tool for an indeterminate ultrasound, it is not practical as a primary screening modality due to higher cost, longer examination time, and more limited availability. Its role is in characterization, not first-line detection.

What’s Next After Ultrasound? Downstream Clinical Workflow

The results of the screening ultrasound dictate the subsequent steps, which range from routine follow-up to urgent specialist referral. The workflow is designed to triage findings based on their likelihood of malignancy.

  • If the study is normal: The patient should continue with her established screening schedule, which is typically annual or semi-annual transvaginal ultrasound and serum CA-125 testing, per guidelines from organizations like the National Comprehensive Cancer Network (NCCN) or the Society of Gynecologic Oncology (SGO).
  • If a simple cyst is found: In a premenopausal woman, simple cysts less than 5 cm are almost always benign and often physiologic. Management typically involves a short-term follow-up ultrasound in 6-12 weeks to ensure resolution or stability, confirming its benign nature. No aggressive intervention is usually needed.
  • If a complex mass or solid lesion is found: This is the most critical outcome and triggers an escalated diagnostic pathway. The next step is immediate referral to a gynecologic oncologist. The specialist will typically order a serum CA-125 (if not already done) and may proceed with a problem-solving MRI of the pelvis without and with IV contrast to better characterize the lesion’s features (e.g., solid components, septations, enhancement patterns). Based on the combined findings, the patient may be recommended for surgical evaluation, often via minimally invasive techniques for both diagnosis and treatment.

This structured approach ensures that normal physiologic changes do not lead to unnecessary anxiety or surgery, while truly suspicious findings are managed aggressively by the appropriate subspecialist.

Pitfalls to Avoid and When to Escalate

Navigating high-risk ovarian screening requires careful interpretation to avoid common errors.

  • Over-interpreting functional cysts: A corpus luteum can appear complex with internal echoes and peripheral vascularity. It is crucial to consider the patient’s menstrual cycle phase and recommend a follow-up scan post-menses to confirm resolution before escalating care.
  • Ignoring subtle changes: In a high-risk patient, the appearance of a new, small solid nodule or papillary projection, even within a simple-appearing cyst, is a significant finding that warrants immediate further evaluation.
  • Relying solely on CA-125: This tumor marker has low sensitivity for early-stage disease and low specificity in premenopausal women, as it can be elevated by benign conditions like endometriosis or fibroids. It should always be interpreted in conjunction with imaging findings.

When to Escalate: Any adnexal lesion with solid components, thick septations (>3 mm), significant internal vascularity on Doppler, or associated findings like ascites or peritoneal nodules is highly suspicious for malignancy. These findings mandate immediate referral to a gynecologic oncologist for further management, which will likely involve surgical evaluation.

Related ACR Topics and Tools

This article focuses on a single clinical scenario. For a comprehensive overview of all patient presentations related to this topic, please see the parent guide. The tools below can assist in navigating other scenarios, understanding imaging techniques, and discussing radiation safety.

Frequently Asked Questions

Why is ovarian cancer screening not recommended for average-risk premenopausal women?

For average-risk women, the lifetime risk of ovarian cancer is low (about 1 in 78). The available screening tests (ultrasound and CA-125) have a high rate of false positives, which can lead to significant patient anxiety and unnecessary, potentially harmful surgeries. Large clinical trials have shown that for the general population, the harms of screening outweigh the benefits.

How often should high-risk premenopausal women be screened?

Most guidelines from organizations like the NCCN and SGO recommend screening every 6 to 12 months for high-risk women, typically starting between ages 30 and 35, or 5-10 years earlier than the earliest age of ovarian cancer diagnosis in the family. The screening usually consists of both a transvaginal ultrasound and a serum CA-125 blood test.

What specifically defines a woman as ‘high risk’ for ovarian cancer?

A woman is considered high risk if she has a known pathogenic or likely pathogenic variant in a cancer susceptibility gene like BRCA1 or BRCA2, or genes associated with Lynch syndrome. A strong family history, such as having multiple first- or second-degree relatives with ovarian, breast, colon, or endometrial cancer, can also place a woman in the high-risk category, often confirmed through genetic counseling and risk assessment models.

Is the CA-125 blood test still used with ultrasound for screening in this group?

Yes, for high-risk screening, CA-125 is typically performed along with transvaginal ultrasound. While it has limitations, particularly in premenopausal women where it can be falsely elevated, a rising trend over time can be an early indicator of malignancy. It is interpreted in the context of the ultrasound findings, not as a standalone test.

If the screening ultrasound is abnormal, is the next step always surgery?

No, not always. The next step depends on the nature of the abnormality. A simple-appearing cyst is often monitored with a follow-up ultrasound to see if it resolves, as most do. If a lesion has suspicious features, the next step is typically a referral to a gynecologic oncologist and further characterization with an MRI. Surgery is reserved for lesions that remain highly suspicious for malignancy after a full diagnostic workup.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 26, 2026